POU class 6 homeobox 1Genealiases: BRN5 · MPOU · TCFB1
Q-omics provides the consensus-scored POU6F1 profile across patient tissues and cancer cell-line models. POU6F1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, POU6F1 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, POU6F1 RNA expression shows 20,028 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LGG, BLCA, and KIRP as cancer lineages where POU6F1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POU6F1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POU6F1 survival associations across molecular data types. POU6F1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POU6F1 RNA expression–survival associations across cancer types. High POU6F1 expression shows unfavorable associations in COAD, but favorable associations in LGG, SKCM, UCS, HNSC and PAAD. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for POU6F1 RNA expression.
This table summarizes POU6F1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for POU6F1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POU6F1 shows lower tumor expression in BLCA, THCA, LUSC, UCEC, BRCA and LUAD. The BLCA box plot shows higher POU6F1 RNA expression in normal versus tumor tissue (log2 FC = −2.255, t-test p < 0.001).
This table shows molecular features associated with POU6F1 in patient tissues and cancer cell lines. In patient samples, POU6F1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, POU6F1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
